NEWS
View news from our Featured Companies.
InfuSystem Announces Agreement with Solo-Dex for Continuous Peripheral Nerve Block Catheters
ROCHESTER HILLS, Mich. - InfuSystem Holdings, Inc. (NYSE American: INFU), ("InfuSystem" or the "Company), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today...
ChromaDex to Report Fourth Quarter 2021 Financial Results on Wednesday, March 9, 2022
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed. March 9, 2022 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended December 31, 2021. The financial results will be reported in a press release...
Scientific Industries Reports Financial Results for Second Quarter of Fiscal Year 2022
Bioprocessing Reports Strong Revenue GrowthContinued Focus Driving Digitally Simplified Bioprocessing GrowthBOHEMIA, NY / February 17, 2022 / Scientific Industries, Inc. (OTCQB:SCND), a life sciences tool provider, and a developer of digitally simplified bioprocessing...
INVO to Launch Additional INVO Center in Tampa, Florida
Tampa INVO Center to focus on advanced fertility care utilizing INVOcell®SARASOTA, Fla. and TAMPA, Fla., Feb. 16, 2022 -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with...
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2021
Conference Call Scheduled for Wednesday, February 23, 2022 at 9:00 AM ETPORTLAND, Maine, Feb. 16, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven...
Mogo to Participate in the Jefferies Payments & FinTech Summit
VANCOUVER, British Columbia - Mogo Inc. (NASDAQ:MOGO) (TSX:MOGO) ("Mogo" or the "Company"), a digital payments and financial technology company, today announced that Greg Feller, Co-founder and President, will be participating in the Jefferies Payments & FinTech...
Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results
Quarterly Net Revenue Increased 53% Year-over-year to $23.1 MillionPREVEnt Pivotal Study for AR101 in Vascular Ehlers-Danlos Syndrome On-track to Begin in Mid-2022Initiation of Randomized, Sham-controlled Study of Healight in Patients with SARS-CoV-2 to Begin...
S&W Announces Second Quarter Fiscal 2022 Financial Results
LONGMONT, Colo., Feb. 10, 2022 -- S&W Seed Company (Nasdaq: SANW) today announced financial results for the second quarter of fiscal year 2022 ended December 31, 2021. "We are gaining increased enthusiasm for the outlook of our Double Team sorghum trait technology...
Modular Medical Announces Pricing of $15 Million Public Offering and Uplisting to the Nasdaq Capital Market
SAN DIEGO, CA / February 10, 2022 / Modular Medical, Inc., (NASDAQ:MODD) (the "Company" or "Modular Medical"), a development-stage insulin pump company focused on providing insulin delivery without complexity to increase pump adoption and reduce the burden of diabetes...
InfuSystem Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2021
Full Year 2021 vs. Full Year 2020: Net Revenues: $102.4 million, a 5% increase Net Income: $1.4 million, Adjusted EBITDA: $24.0 million ROCHESTER HILLS, Mich. - InfuSystem Holdings, Inc. (NYSE American: INFU), ("InfuSystem" or the "Company"), a leading national health...
InfuSystem to Report Preliminary Fourth Quarter and Full Year 2021 Financial Results on February 10, 2022
Investor Conference Call to be held 9:00 a.m. Eastern Time ROCHESTER HILLS, Mich. - InfuSystem Holdings, Inc. (NYSE American: INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical...
INVO Bioscience Eyes +20 U.S. Cities To Expand Rollout Of Advanced Infertility Treatment ‘INVO Centers’
SAN FRANCISCO, CA / February 9, 2022 / Today, the global fertility market is a multi-billion industry, yet remains severely underserved, with estimates suggesting more than 90% of couples in need of infertility treatment going without care. INVO Bioscience...
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
FDA Agreed to PolyPid Request for the Addition of an Unblinded Interim Analysis in SHIELD I once 750 Patients Complete their 30-day Follow-up Recruitment Progressing as Planned with Approximately 680 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in...
ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinamide Riboside
Newly granted continuation patent provides additional intellectual property protection for ChromaDex's Niagen® (patented nicotinamide riboside) ingredient LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced that it was granted a continuation patent,...
ARIANNE PHOSPHATE EXPLORING THE USE OF ITS HIGH-PURITY CONCENTRATE FOR ALTERNATIVELY DERIVED FERTILIZERS
-the Company is working with Cegep Riviere-de-Loup to develop a new breed of fertilizer DAN: TSX-V (Canada)JE9N: FSE (Germany)DRRSF: OTC (USA) SAGUENAY, QC, Feb. 8, 2022 /CNW Telbec/ - Arianne Phosphate (the "Company" or "Arianne") (TSXV: DAN) (OTC: DRRSF) (FRANKFURT:...
Kiora Pharmaceuticals Announces Participation at 2022 BIO CEO & Investor Conference
Salt Lake City, Utah--(February 8, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced today that Brian M. Strem, Ph.D, President and CEO of Kiora, will present a Company overview at the BIO CEO & Investor Conference on...
IRADIMED Announces Special $1.00 Per Share Cash Dividend
WINTER SPRINGS, Fla., Feb. 07, 2022 -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD), announced that its Board of Directors approved a special cash dividend of $1.00 per share on the Company's outstanding common stock. This special cash dividend is payable on...
IRADIMED CORPORATION Announces Fourth Quarter 2021 Financial Results
Reports fourth quarter 2021 revenue of $11.9 million, GAAP diluted EPS of $0.31 and non-GAAP diluted EPS of $0.33Announces full-year and first quarter 2022 financial guidance WINTER SPRINGS, Fla., Feb. 04, 2022 -- iRadimed Corporation (the "Company") (NASDAQ: IRMD), a...
S&W Seed Company to Report Second Quarter Fiscal Year 2022 Financial Results on Thursday, February 10, 2022
Conference call to be conducted on Thursday, February 10, 2022, at 11:00AM ET LONGMONT, Colo., Feb. 3, 2022 -- S&W Seed Company (Nasdaq: SANW) will report financial results for its second quarter fiscal year 2022, ended December 31, 2021, on Thursday, February 10,...
INVO Bioscience Expands U.S. Commercialization Efforts
Focused on addressing underserved patients within the fertility marketplaceSARASOTA, Fla., Feb. 3, 2022 -- INVO Bioscience, Inc. (NASDAQ: INVO) ("Company") ("INVO"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with...
SenesTech Announces ContraPest® Deployment at California Wildlife Preserve
Latest in a growing number of deployments in the zoo and animal sanctuary market. ContraPest®, the one and only EPA approved birth control product for rats, addresses the unique challenges controlling rat populations in animal settings.PHOENIX, Feb. 3, 2022 --...
Reviva Pharmaceuticals Announces First Patients Dosed in Pivotal Phase 3 Study and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of Schizophrenia
- RECOVER is a Phase 3, randomized, double-blind study with registrational intent - - Reviva anticipates expanding the clinical development of brilaroxazine into other neuropsychiatric indications - CUPERTINO, Calif., Feb. 01, 2022 -- Reviva Pharmaceuticals Holdings,...
Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board
Salt Lake City, Utah--(February 1, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced today the appointment of Erin Parsons as a new independent Director of its Board of Directors (the "Board"). Separately, the Executive Chairman,...
Aytu BioPharma Completes $15 Million Debt Refinancing
ENGLEWOOD, CO / January 31, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that it has entered into an agreement with the Avenue Venture Opportunities Fund, L.P., an...
ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients
ChromaDex's research & development program reaches 100 published peer-reviewed studies on Niagen® and other ingredients LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) celebrates the ChromaDex External Research Program's (CERP™) 100th published...